Antiviral Research

Antiviral Research (Antivir. Res.) is published by Elsevier as the official journal of the International Society for Antiviral Research. It was founded in 1981 by Erik De Clercq and Alfons Billiau at the Rega Institute in Leuven, Belgium, concentrates on experimental work on antiviral drugs and vaccines, is a hybrid title, and had a 2025 impact factor of 4.3.《抗病毒研究》（Antiviral Research''''，缩写 Antivir. Res.''）是爱思唯尔出版、（国际抗病毒研究学会）的官方刊物，1981 年由（Erik De Clercq）与（Alfons Billiau）创办于比利时鲁汶的（Rega）研究所。该刊以抗病毒药物与疫苗的实验研究为主，现为混合出版，二〇二五年影响因子为 4.3。

Scope

The journal's editorial position is that a demonstrable antiviral effect must be at the centre of a paper: whether the work sits in chemical synthesis, animal modelling or preclinical evaluation, it must give reproducible evidence of activity against a specific virus. Coverage runs from compounds to vaccines, and concentrates on:本刊的取稿立场是「以可检验的抗病毒效应为核心」：无论一项工作落在化学合成、动物模型还是临床前评价环节，都必须给出针对特定病毒的可重复效应证据。收文覆盖从化合物到疫苗的完整链条，重点包括：

• Antiviral drugs and antibodies: design and synthesis of small molecules and nucleoside analogues, neutralising antibodies and modulators of the host response, and evaluation of activity in vitro and in vivo.抗病毒药物与抗体： 小分子与核苷类药物的设计合成、中和抗体与宿主应答调节剂、体外与体内药效评价。

• Target discovery and validation: druggability of viral enzymes and host factors, structural and mechanistic analysis of targets, and validation and chemical intervention of new targets.靶点发现与验证： 病毒酶与宿主因子的成药性研究、靶点结构与机制解析、新靶点的验证与化学干预。

• Mechanism of action: the mechanism and biochemical pathways of drug action, key steps in the viral replication cycle, and structure-function relations.作用机制： 药物作用机制与生化通路、病毒复制周期的关键步骤、结构与功能的对应关系。

• Resistance and countermeasures: evolutionary routes of resistant virus and their surveillance, the structural basis of resistance, and combination therapy and strategies to overcome it.耐药与对策： 耐药病毒的进化路径与监测、耐药机制的结构基础、联合用药与克服耐药的策略。

• Animal models and vaccines: animal models of viral infection and the evaluation of efficacy, new and improved human vaccines, and veterinary vaccines and the control of viral disease in vertebrates.动物模型与疫苗： 病毒感染的动物模型与药效评价、新型与改良人用疫苗、兽用疫苗与脊椎动物病毒病防治。

• Safety evaluation: toxicology and safety of candidates, drug metabolism and exposure, and the standardised presentation of preclinical safety data.安全性评价： 候选药物的毒理与安全性、药物代谢与暴露量、临床前安全性数据的规范化呈现。

The journal is hybrid and the gold open access article processing charge is 3,650 US dollars. The publisher reports four days to first decision, thirty-three days to a decision after review and eighty-one days to acceptance, and publishes no acceptance rate.本刊为混合出版，金色开放获取的文章处理费为三千六百五十美元；出版方公布投稿至首次决定四天、复审后决定三十三天、投稿至接收八十一天，未公布录用比例。^[1]

History

• Founding (1981): the journal was founded in 1981 by Erik De Clercq and Alfons Billiau at the Rega Institute in Leuven, who shared the chair and divided medicinal chemistry from interferon and biologicals创刊（1981年）： 1981 年由（Erik De Clercq）与（Alfons Billiau）在鲁汶（Rega）研究所创办，两人分头负责药物化学与干扰素及生物制品方向并共同主编，创刊当年发表论文三十九篇。 thirty-nine papers appeared in the first year.^[2]

• Alliance with the society (1987): the journal predates the International Society for Antiviral Research by six years与学会结盟（1987年）： 本刊早于（国际抗病毒研究学会）六年问世，该学会 1987 年成立、1988 年召开首届国际抗病毒研究大会，此后本刊成为其官方刊物，学会年会与上刊内容长期相互衔接。 the society was established in 1987 and held its first international conference in 1988, after which this journal became its official title, with the annual meeting and the journal's contents closely linked ever since.^[3]

• Growth and process change (2007–2012): annual output rose from thirty-nine papers at the launch to 116 in 2007 and 253 in 2017体量增长与流程改造（2007—2012年）： 年发文量由创刊时的三十九篇增至 2007 年一百一十六篇、2017 年二百五十三篇；2012 年起启用电子投稿与自动分稿系统，同时停止出版会议摘要专刊，改为每年至少两期主题特刊。 from 2012 the journal moved to electronic submission with automated triage, ceased publishing conference abstract supplements, and moved to at least two thematic special issues a year.^[2]

• Metrics and indexing: the impact factor is 4.3 and the CiteScore 7.8. The journal is indexed in Scopus, MEDLINE and the Science Citation Index Expanded, one of the few specialist antiviral titles carried by both the medical and the chemical literature systems.指标与收录： 影响因子 4.3、引用分数 7.8；本刊被 Scopus、MEDLINE 与科学引文索引扩展版收录，是抗病毒方向少数同时被医学与化学文献体系覆盖的专业刊物。^[1]

Editors

The journal is led by an editor-in-chief supported by co-editors and a board divided by virus family, with several long-serving senior figures among its members. Each of the three successions since the founding has accompanied a shift of emphasis, from medicinal chemistry outwards into virology and host immunity.本刊由一名主编主持，下设若干共同主编与按病毒科属分工的编委，编委中不乏长期任职的资深学者；创刊以来的三次主编交接都伴随着研究重心的迁移，从药物化学逐步扩展到病毒学与宿主免疫。^[4]

• Present editor-in-chief (since 2022): Subhash Vasudevan holds the chair. He is at the Duke-NUS Medical School in Singapore, works on flaviviruses and antiviral drug discovery, and since taking over in 2022 the journal has visibly increased its coverage of arboviruses.现任主编（2022年起任）： （Subhash Vasudevan）任主编，供职于新加坡（Duke-NUS）医学院，研究黄病毒与抗病毒药物发现，2022 年接任后本刊在虫媒病毒方向的收录明显增加。^[4]

• Founding editor and predecessor: the founder Erik De Clercq led the journal from 1981 to 2011 and shaped it for three decades创刊主编与前任： 创刊人（Erik De Clercq）自 1981 年主持至 2011 年，是本刊三十年间的主要塑造者；（Mike Bray）自 2012 年任职至 2022 年，任内推动本刊进入生物安全与突发疫情相关研究的快速通道。 Mike Bray held the chair from 2012 to 2022 and during his term pushed the journal towards fast-track handling of biosecurity and outbreak-related work.^[5]

• Tradition of co-editors: the journal has repeatedly appointed co-editors to cover the two strands of small-molecule drugs and biologicals共同主编传统： 本刊历史上多次设置共同主编，分别负责小分子药物与生物制品两条线，（Richard Whitley）自 1987 年起、（Earl Kern）自 2007 年起曾任共同主编，反映本刊对两类研究并重的传统。 Richard Whitley from 1987 and Earl Kern from 2007 served in that capacity, reflecting the journal's long-standing commitment to both lines of research.^[2]